AN2 Therapeutics Reports Q4/FY25 Results, Extends Runway to 2029, Advances Multiple Phase 2 Programs

summarizeSummary

AN2 Therapeutics reported its Q4 and full-year 2025 financial results, highlighted by a reduced annual net loss and a cash runway extended into 2029, alongside significant advancements across its clinical pipeline.

check_boxKey Events

• Q4 and Full Year 2025 Financial Results

  Reported a net loss of $8.7 million for Q4 2025 (vs. $7.5 million in Q4 2024) and a full-year net loss of $35.2 million (a reduction from $51.3 million in FY 2024). R&D expenses decreased year-over-year for the full year.

• Cash Runway Extended to 2029

  Ended 2025 with $60.0 million in cash, cash equivalents, and investments. A March 2026 private placement of approximately $40 million is projected to extend the company's operational runway into 2029.

• Multiple Phase 2 Programs Advancing

  Plans to initiate Phase 2 studies for oral epetraborole in polycythemia vera (3Q26) and M. abscessus complex lung disease (1Q26). A Phase 2 proof-of-concept study for AN2-502998 in chronic Chagas disease is also planned for 2026, pending Phase 1 results.

• Oncology Pipeline and Global Health Initiatives

  On track to advance two boron-based oncology candidates (PI3Kα and ENPP1) into development in 2026. The company also continues its research collaboration with GSK for tuberculosis, supported by third-year funding from the Gates Foundation.

auto_awesomeAnalysis

AN2 Therapeutics reported its fourth quarter and full-year 2025 financial results, showcasing a reduced annual net loss and a significantly extended cash runway into 2029, largely due to a recent $40 million private placement. This financial stability underpins substantial progress across its clinical pipeline, with three Phase 2 studies (Polycythemia Vera, M. abscessus complex lung disease, Chagas disease) expected to initiate in 2026, alongside the advancement of two boron-based oncology candidates. For a clinical-stage biopharmaceutical company, securing a long cash runway and demonstrating active pipeline progression are critical de-risking factors that can positively impact investor confidence.